Filtricine, Inc. is developing Tality, a proprietary nutritional regimen designed to deprive cancer cells of non-essential amino acids while providing complete nutrition for patients undergoing cancer treatment. This approach aims to enhance patient quality of life and support cancer management through clinically investigated meal replacements, including soups, shakes, and bars.
Funding
$8.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer cells require non-essential amino acids (NEAAs) to survive, which are typically obtained from a patient's diet. Current cancer treatments often neglect the role of nutrition in managing the disease and supporting patient well-being.
Solution
Filtricine, Inc. is developing Tality, a proprietary nutritional regimen designed to manage cancer by depriving cancer cells of NEAAs while providing complete nutrition for patients undergoing treatment. Tality is formulated as a range of replacement meals, including soups, shakes, and bars, that are designed to be nutritionally complete while excluding specific NEAAs. This approach aims to improve patient quality of life by providing essential nutrients while potentially limiting the growth and spread of cancer cells. Tality is currently undergoing clinical trials to evaluate its safety and efficacy in cancer patients.
Target Audience
The primary target audience includes cancer patients undergoing treatment and healthcare professionals involved in cancer care, such as oncologists and dietitians.
Features
- Formulated to exclude non-essential amino acids (NEAAs) required by cancer cells
- Nutritionally complete meal replacements in soup, shake, and bar formats
- Designed to support cancer management through targeted nutrient deprivation
- Currently undergoing clinical trials to assess safety and efficacy